Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why CureVac Stock Is Tumbling Today

By Keith Speights - Oct 12, 2021 at 11:10AM

Key Points

  • CureVac is withdrawing its lead COVID-19 vaccine candidate from the European approval process.
  • The decision came after the European Medicines Agency refused to fast-track the review process.
  • CureVac now plans to work with GlaxoSmithKline to develop second-generation vaccine candidates.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is throwing in the towel on its first-generation COVID-19 vaccine candidate.

What happened

Shares of CureVac ( CVAC 10.32% ) were tumbling 7.4% as of 11 a.m. EDT on Tuesday after falling as much as 13% earlier in the morning. The decline came after the company announced it's withdrawing COVID-19 vaccine candidate CVnCoV from the European Medicines Agency's approval process. CureVac plans to now focus on the development of  second-generation COVID-19 vaccine candidates with its partner GlaxoSmithKline ( GSK 1.49% )

So what

In June, CureVac released final data from a phase 2b/3 clinical study that showed CVnCoV had an overall efficacy of 48%. That level is well below the efficacy achieved by other authorized COVID-19 vaccines. However, CureVac initially hoped to win European approval despite the lower efficacy.

A healthcare professional giving a shot to a person.

Image source: Getty Images.

The company chose to throw in the towel on CVnCoV after the European Medicines Agency communicated that it wouldn't fast-track the approval process for the vaccine candidate. As a result, the earliest possible European approval for the experimental vaccine would have been in the second quarter of next year. CureVac expects its second-generation vaccine candidates will be in late-stage clinical studies by then.

The decision to withdraw CVnCoV from the EMA approval process came at a cost, though. The company had an advance purchase agreement with the European Commission to supply 405 million doses of the vaccine if it secured approval.

Now what

Can the vaccine stock recover? Perhaps. CureVac and GlaxoSmithKline are accelerating their efforts to develop a second-generation COVID-19 vaccine. The companies hope to begin clinical development within the next few months with the goal of winning regulatory approval sometime next year. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CureVac N.V. Stock Quote
CureVac N.V.
$45.00 (10.32%) $4.21
GlaxoSmithKline plc Stock Quote
GlaxoSmithKline plc
$42.38 (1.49%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.